73 results
424B5
TRML
Tourmaline Bio Inc
26 Jan 24
Prospectus supplement for primary offering
4:08pm
of death globally. Preventing major adverse cardiovascular events (“MACE”), such as death, nonfatal myocardial infarction or nonfatal stroke, has
424B5
TRML
Tourmaline Bio Inc
24 Jan 24
Prospectus supplement for primary offering
9:20pm
. Atherosclerotic cardiovascular disease (“ASCVD”) is a leading cause of death globally. Preventing major adverse cardiovascular events (“MACE … ”), such as death, nonfatal myocardial infarction or nonfatal stroke, has the potential to significantly reduce global cardiovascular disease burden. IL-6 has been
8-K
EX-99.2
7nwrg9v7a8semxaz
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
EX-99.1
0g6kluqec 3dd37k
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
EX-99.1
1kzdsy
8 Jan 24
Regulation FD Disclosure
9:19am
8-K
cqdv wl0z4hzgy8c
27 Oct 23
Departure of Directors or Certain Officers
5:17pm
8-K
EX-10.1
3racai18o7cfhdyslb8
27 Oct 23
Departure of Directors or Certain Officers
5:17pm
8-K
EX-10.3
6fuw8a7 oe6v
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
8-K
wycranwmbl
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
8-K
EX-10.2
kcba0
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
8-K
EX-99.1
o4x7eokp4xn zs2cs1h
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
8-K
EX-10.4
fecu91jjsezg
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
8-K
EX-10.8
vinmmtvnhmtom5
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
8-K
EX-10.7
4zdowtc 8eul
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
425
n7zo7 0fl0yc4
26 Sep 23
Business combination disclosure
8:24am